Paratek Pharmaceuticals, Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics based upon tetracycline chemistry. The firm's lead product candidates include Omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. Paratek has a collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. One year after withdrawing its own IPO in 2013, Paratek Pharmaceuticals Inc. did a reverse merger with public neuroscience firm Transcept Pharmaceuticals Inc. Transcept Pharmaceuticals itself in 2008 had done a reverse merger with publicly traded Novacea
